

December 12, 2005

Targepeutics, Inc. Announces New Approaches to Brain Tumor Therapy consortium (NABTT) Relationship

Targepeutics presented at the semi-annual New Approaches to Brain Tumor Therapy consortium (NABTT) business meeting held in Philadelphia on December 1, 2005. Targepeutics is planning to conduct a Phase I clinical trial for high-grade glioma with this group of top medical institutions in early 2007.

Targepeutics' lead compound, Glioblast-13, is the more specific, second generation technology to the current IL-13PE38QQR compound (wildtype IL-13) that is currently in phase III clinical trials. Glioblast 13 is a patented, mutated form of interleukin-13 that specifically targets receptors on brain cancer cells while sparing the normal cells that do not express the target

With NABTT's heavy involvement and using its experience from past trials, the clinical protocol for Glioblast-13 is near completion for presentation to the FDA in an upcoming pre-IND meeting with the Agency the first quarter of 2006.

Targepeutics is a biopharmaceutical company developing selective molecularly targeted therapeutics to fight cancer. Currently, Targepeutics' three pharmaceutical platforms are Targepeutics' Genetically Engineered Interleukin-13, Immunotherapy (applications in cancer and asthma), and Anti-tumor Progression (targeting growth and ability of solid tumors to create new blood vessels). Targepeutics is based in Hershey, Pennsylvania and is privately held.

For more information, please contact: Sil Lutkewitte, President, at slutkewitte@targepeutics.com